Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
about
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaMechanisms and functions of Tet protein-mediated 5-methylcytosine oxidationEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cellsConnections between TET proteins and aberrant DNA modification in cancerThe TET2 interactors and their links to hematological malignanciesJAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.Recurrent DNMT3A mutations in patients with myelodysplastic syndromesTET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Assessment of PET/CT in multifocal myeloid sarcomas with loss of TET2: a case report and literature reviewRecent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaTen-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in miceDeletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignanciesThe behaviour of 5-hydroxymethylcytosine in bisulfite sequencingClonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review.Active DNA demethylation: many roads lead to Rome.A mathematical framework to determine the temporal sequence of somatic genetic events in cancerCurrent outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.Pathogenic microRNA's in myeloid malignancies.Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cellsMolecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesTET proteins and the control of cytosine demethylation in cancer.CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemiaGenetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma.Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.TET proteins and 5-methylcytosine oxidation in hematological cancersCytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
P2860
Q24306181-2834198C-71D0-4B72-9F99-51479A6EDF9FQ26768600-E143F049-BE41-4020-96E4-A49AB7DFE83DQ26823896-118897D6-C011-43F9-B85B-01A90BBDE976Q26828777-DEAB83D8-8A17-41C5-86FE-459B5CFCA30AQ26851510-A0C0443A-5C5F-4088-9DAA-0D8F1087D0A9Q26865671-63604DF9-6805-4195-BF90-8CA63EDCD0BCQ27002485-5DD06C2F-790A-4B0A-B67C-159C9EF1D1CFQ27012572-993604FC-8826-497B-ADA5-6D21E107A71DQ27687464-8DA58792-9A2A-4A8F-901E-6D4F1C0D5DC1Q27851621-8E5C022E-175C-49A8-B1E8-169B5264D5D6Q27851629-78F3D01E-3778-4DBF-B189-DC10089A8887Q27853009-8DB40150-2F4B-4E7F-896D-6598AEE85D25Q28069893-A4650BD3-8947-44B6-BE93-18FDAD2764EFQ28307278-C0E0578B-CCD3-4081-BB31-4982F283443DQ28511594-AEFDCB31-41FA-4541-BE78-2185D632A993Q28591763-E3D9B364-D636-4CFF-9A7E-2FD65BAF612DQ28749183-99191A01-A4C4-4885-9621-495FF94C1359Q33558105-DCE3EE82-92E3-4650-9BDF-BC4362D07E8DQ33620407-AD7E8E43-1678-4FEE-98E9-71EFDB9D7B52Q33647411-5A811951-3155-4C92-A8A3-533297FE665BQ33699967-8F6287D7-65BB-44FC-86BE-56C2F27B1B41Q34129576-3B354015-8EB9-4C40-919D-E7F75894C4C6Q34200279-2B02B267-149A-45FD-AFF2-6E0E7F90E184Q34302770-150DB406-6F07-425E-B6D8-1F5577E39BD4Q34355585-722AE390-9D51-4824-80B3-0126C53FC980Q34541057-B21C2814-A03F-48E8-A0FA-93844C8363ECQ34647637-296AE229-3AF9-47BB-908E-8445F6BABDBDQ34700714-D5BADFE1-F044-4D87-9190-324879F6F918Q34997720-70889DF1-CE76-40FC-B5E3-757E9F54749DQ35021377-72E5D7FF-759B-487D-8A19-F380408D1B18Q35030952-3DAB18A7-75CE-459C-B7D4-476A555CF1DFQ35069556-2140D6E5-03EE-48C6-8F01-B63054C7E56CQ35797589-AAB2CC8A-CE8C-46E9-8BC5-362998D44522Q35862540-95564E7B-07B5-4FAF-99F9-EFD9D1A0A316Q35911141-2F3B3139-5D2D-4785-8996-362B4918D4E5Q35942167-9561EB21-99E4-4C48-8464-62B9B4D5964BQ36179524-9DA52FF9-9CA1-4A8E-A880-355706C34140Q36197509-A976184A-FD7D-4AA6-9198-F3F78D54C13BQ36303438-8AF498BC-1268-4209-B0CE-96245547E7B0Q36303447-3089211C-BE1A-4E09-9A1A-63638E6568E8
P2860
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@ast
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@en
type
label
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@ast
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@en
prefLabel
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@ast
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@en
P2093
P2860
P356
P1433
P1476
Detection of mutant TET2 in my ...... s: CMML, MDS, MDS/MPN and AML.
@en
P2093
A Pardanani
C A Hanson
D G Gilliland
M M Patnaik
O Abdel-Wahab
R L Levine
P2860
P2888
P304
P356
10.1038/LEU.2009.59
P577
2009-03-19T00:00:00Z